NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants
2023年8月21日 - 7:00PM
ビジネスワイヤ(英語)
August Issue of Lancet Medical Journal Features
Breakthrough Study Decoding Immunological Challenges of
Xenotransplantation
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider
of life science tools for discovery and translational research,
announced today that a team of globally renowned researchers
utilized two NanoString platforms, the nCounter® Analysis System
and GeoMx® Digital Spatial Profiler, to decode the immune response
following the transplantation of genetically modified pig kidneys
into humans. The groundbreaking study featured in the August issue
and an accompanying commentary of The Lancet medical journal
produced fundamental new data on the first pig-to-human organ
transplants. Insight from the 2021 study contributes to the ongoing
success and duration of follow-on pig-to-human transplants heralded
last week in The New York Times and Wall Street Journal.
The seminal research led by Alexander Loupy, MD, Ph.D., in
cooperation with a global medical team, unravels the complex
molecular characteristics of antibody-mediated rejection following
the first and second-ever pig-to-human kidney transplants that
occurred in 2021 at NYU Langone Transplant Institute. In an
accompanying Lancet commentary, scientists praised the team “for
laying the foundation for deeper assessment of xenoimmunology and
establishing immunological research pathways to advance
xenotransplantation.” They also commented on the importance of
“state-of-the-art spatial techniques” to decipher transcriptional
immune activation.
“We gained vital data and, for the first time ever, we were able
to see what is happening immunologically in defined regions of the
tissue,” said Dr. Loupy. “This data, enabled by NanoString’s
platforms and an Allo - Xeno gene expression repository, allowed us
to understand both the similarities and the novel aspects
underpinning organ rejection in xenograft transplantation compared
to human organ transplantation. NanoString’s nCounter and GeoMx
instruments harmonized to create a holistic view of the immune
response.” Researchers from the Paris Institute for Transplantation
and Organ Regeneration, University of Paris, France’s National
Institute of Health and Medical Research contributed to the
study.
Xenotransplantation, the process of transplanting organs from
animals to humans, is a crucial area of research dedicated to
addressing the profound shortage of healthy human organs available
for transplant patients. The groundbreaking experimental transplant
surgeries performed by Dr. Robert Montgomery at NYU since 2021
involve patients in a state of brain death. Their families and
ethical committees have consented to artificially maintain blood
circulation during the transplants to advance scientific knowledge
on xenotransplantation with the hope of offering more healthy
organs for future patients.
The research team, including co-first authors of The Lancet
study, Dr. Valentin Goutaudier and Dr. Alessia Giarraputto
characterized the human immune response to the porcine kidney using
bulk tissue transcriptome profiling on the nCounter Analysis
System. Scientists used the nCounter Human Organ Transplant Panel,
a process NanoString developed with the Banff International
Classification Consortium. It is used by nearly one hundred global
research institutions. The panel was adapted to xenotransplants by
using bioinformatics-based pig and human gene sequences with
homologies alignment. This analysis revealed a molecular
architecture of antibody-mediated rejection, including
interferon-gamma response, endothelial activation, macrophage
activation, and injury repair response in the xenografts.
The GeoMx Digital Spatial Profiler was used next to isolate the
immune response to specific regions of the kidney. The GeoMx Whole
Transcriptome Assay revealed that antibody-mediated injury was
mainly located in the glomeruli of xenografts, with significant
enrichment of transcripts associated with monocytes, macrophages,
neutrophils, and NK cells.
Drs. Loupy and Montgomery say their findings represent a
treasure trove of new information for optimizing genetically
modified pig models that may be useful in developing more advanced
immunosuppressive treatments for future recipients of
xenografts.
“An estimated 100,000 people are waiting for organ transplants
in the United States. Thousands die on the wait list. Numbers like
these drive us at NanoString to provide researchers with the tools
they need to find innovative solutions to solve extraordinary
medical challenges,” commented Brad Gray, President and CEO of
NanoString. “We congratulate Dr. Loupy and his extended team on
their findings and celebrate the on-going successful studies in
humans.”
About NanoString Technologies, Inc.
NanoString Technologies, is a leader in spatial biology, offers
an ecosystem of innovative discovery and translational research
solutions, empowering our customers to map the universe of biology.
The GeoMx® Digital Spatial Profiler is a flexible and consistent
solution combining the power of whole tissue imaging with gene
expression and protein data for spatial whole transcriptomics and
proteomics. The CosMx™ Spatial Molecular Imager is a single-cell
imaging platform powered by spatial multiomics enabling researchers
to map single cells in their native environments to extract deep
biological insights and novel discoveries from one experiment. The
AtoMx™ Spatial Informatics Platform is a cloud-based informatics
solution with advanced analytics and global collaboration
capabilities, enabling powerful spatial biology insights anytime,
anywhere. At the foundation of our research tools is our nCounter®
Analysis System, which offers a secure way to easily profile the
expression of hundreds of genes, proteins, miRNAs, or copy number
variations, simultaneously with high sensitivity and precision. For
more information, visit www.nanostring.com.
The NanoString logo, NanoString, NanoString Technologies, GeoMx,
CosMx and nCounter are trademarks or registered trademarks of
NanoString Technologies, Inc., in the United States and/or other
countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230821118527/en/
Doug Farrell Vice President, Investor Relations & Corporate
Communications dfarrell@nanostring.com Phone: 206-602-1768
NanoString Technologies (NASDAQ:NSTG)
過去 株価チャート
から 4 2024 まで 5 2024
NanoString Technologies (NASDAQ:NSTG)
過去 株価チャート
から 5 2023 まで 5 2024